BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 10:00 am ET. For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event. About Caribou Biosciences, Inc.Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Caribou’s chRDNA genome-editing technology enables superior precision to...

EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that it has entered into a strategic credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) for up to $200 million. “Our strong cash, cash equivalents and marketable securities position, excluding this strategic credit facility, is expected to continue to fund our planned operations into the second half of 2028. Access to this non-dilutive capital further increases our financial strength, providing the Company with strategic and operational flexibility,” said Kristian Humer, Chief Financial...

Extensive Experience Managing Complex Builds Brings Valuable Expertise to Drive Continued GrowthBryan Northrop HeadshotBryan Northrop, Executive Vice President and General Manager of Skanska’s Advanced Technology operating unit.NEW YORK, June 29, 2026 (GLOBE NEWSWIRE) — Skanska, a leading global development and construction firm, today announced the appointment of Bryan Northrop to executive vice president and general manager of the Advanced Technology operating unit, effective July 1. In this role, Northrop will oversee personnel working on semiconductor and data center construction projects in Oregon, Arizona, Virginia and California, as well as in collaboration with regional operating units in Georgia, Ohio and Texas. His appointment strengthens cohesion for Advanced Technology leadership and will ensure accelerated...

NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced today that it has joined the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the 2026 Russell indexes reconstitution, effective after the U.S. market close on June 26, 2026. The Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of April 30, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place until the next semi-annual reconstitution, means automatic inclusion in small-cap Russell 2000® Index as well as the appropriate growth and value style indexes....

BOSTON, June 29, 2026 (GLOBE NEWSWIRE) — GuideAI Health Corp. (“GuideAI” or the “Company“) (Cboe CA: GDAI) is pleased to report that the Company has received final approval to list its common shares (the “Shares”) on Cboe Canada Inc. (“Cboe Canada“). The Company anticipates that the Shares will begin trading at the market open on the 29th of June 2026. Once listed, the Shares are expected to trade under the ticker symbol “GDAI,” with an ISIN of CA40173G1019 and a CUSIP of 40173G101. Investors can trade shares of GDAI through their usual investment channels, including discount brokerages and full-service dealers. “Going public represents an important milestone for GuideAI as we scale our platform and expand access to advanced diagnostic technology,” said Raj...

BOCA RATON, FL, June 29, 2026 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced that DeFi Development Corporation UK PLC (“DFDV UK”) is no longer affiliated with the Company’s treasury accelerator strategy. DFDV has no ongoing exposure to DFDV UK and will not have any role in its future operations or strategic direction. The UK company has separately announced its intention to change its name to Cykel AI PLC and pursue a strategic focus on artificial intelligence. In connection with this separation, DFDV’s revolving credit facility with the UK company has been terminated. For more information, visit defidevcorp.com. To stay up to date with the latest developments and insights, subscribe to...

NEW YORK, June 29, 2026 (GLOBE NEWSWIRE) — The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in Happy City Holdings Ltd (Nasdaq: HCHL) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in HCHL from 04:00:00 on June 12, 2026 to 23:59:00 on June 29, 2026. The last sale price of the company’s shares was $3.96.  More information about the SEC’s order can be found at https://www.sec.gov/files/litigation/suspensions/2026/34-105675.pdf. Trading will remain halted until Happy City Holdings Ltd has fully satisfied Nasdaq’s request for additional information. For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM on the Nasdaq® Web site. For...

HOUSTON, June 29, 2026 (GLOBE NEWSWIRE) — HyOrc Corporation (OTCQB: HYOR), a developer of advanced waste-to-methanol infrastructure, today announced it has been formally profiled by Lux Research, a premier provider of tech-enabled research and advisory services for institutional and industrial sectors. The independent assessment provides tier-one visibility to HyOrc’s First-Of-A-Kind (FOAK) commercial deployment and its highly competitive production economics. Lux Research recognised HyOrc’s targeted green methanol production cost of €350 per tonne. With conventional grey methanol benchmarking at €850 per tonne and the market green premium potentially adding up to an additional €700 per tonne, HyOrc is targeting a highly disruptive cost structure for a sustainable product that commands up to €1,550 per tonne on the open market. Furthermore,...

SAN JOSE, Calif., June 29, 2026 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Nicholas Maestas as Chief Financial Officer, effective immediately. “We are pleased to welcome Nicholas as our new Chief Financial Officer,” said Talat Imran, Chief Executive Officer of Rani. “His depth of experience in biopharma capital markets and corporate strategy makes him well-suited to steward Rani through its next chapter. We also want to again thank Svai Sanford for his steady leadership over the years and his commitment to ensuring a smooth transition.” Mr. Maestas brings more than 10 years of financial leadership experience at clinical-stage biotechnology...

4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections 4FRONT-2 over-enrolled (anticipated N>500), with final patient randomization expected in Q3 2026, reflecting strong interest from investigators and patients 4FRONT-2 52-week topline data is expected in H2 2027EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced enrollment completion for 4FRONT-2, the second Phase 3 clinical trial in our global program, evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD). “Completing global enrollment in both...